Global determinants of cervical cancer outcomes: a health systems analysis

Read full text
Authors: A. Go, Erin Jay G. Feliciano, Juana Martínez, Frances Dominique V. Ho, James Fan Wu, Jonas Willmann, Kaitlyn Lapen, Hannah C Hugo, Yujin Jeong, Angelica Singh, Alberto Busmail Haylock, Nagma Shah
+17 more Janine Patricia G Robredo, Michelle Ann B Eala, Rohan K Patel, Jenny Chen, Megan Lorenza L. Cabaero, Davidi Tawfiles, Shivaek Venkateswaran, Anderson Kirk Nigel G. Tan, Bishal Gyawali, Fabio Y. Moraes, Puneeth Iyengar, Nancy Y Lee, Victoria L. Mango, Neil K. Taunk, Maria Jocelyn Kara Magsanoc-Alikpala, T Peter Kingham, E. Christopher Dee
Cited by: 3
References: 29

Abstract

Objective Significant global health disparities persist in cervical cancer, with over 85% of cases and deaths occurring in low- and middle-income countries (LMICs). In many settings, access to screening, vaccination and treatment is limited. Despite cervical cancer being largely preventable through human papillomavirus (HPV) vaccination and early detection, many women around the world face inadequate healthcare infrastructure, lack of awareness, cultural stigma and gender barriers to seeking care. Therefore, we evaluated global health system metrics that may inform efforts to improve equity in access to cervical cancer care globally. Methods and analysis We derived estimates of age-standardised mortality-to-incidence ratios (MIRs) for female patients with cervical cancer of all ages from the Global Cancer Observatory (GLOBOCAN 2022 database), with complete data available for 121 of 185 countries in the database. We selected the following health system metrics: health spending as a per cent of gross domestic product (GDP), physicians/1000 population, nurses and midwives/1000 population, surgical workforce/1000 population, GDP per capita, Universal Health Coverage Service Coverage Index (UHC index), availability of pathology services, Human Development Index (HDI), Gender Inequality Index (GII) (a combined metric of health, empowerment and economic agency), radiotherapy centres/1000 population, out-of-pocket expenditure as percentage of current health expenditure, availability of cervical cancer screening, and HPV coverage. We evaluated the association between MIR and each metric using univariable linear regressions. To account for multiple comparisons, a Bonferroni correction using a p

Fields of Study & Subjects

Cervical Cancer and HPV Research Advances in Oncology and Radiotherapy Global Cancer Incidence and Screening

Publication details

Journal / source
BMJ Oncology
Publisher
BMJ
Volume
5
Issue
1
Pages
e000975–e000975
Publication date
1 January 2026
Language
EN